Does J1575 require prior authorization?

Yes, J1575 requires prior authorization (medium confidence). Conditional coverage; review criteria to confirm PA need.

What is the Medicare reimbursement rate for J1575?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`J1575`, Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin

HCPCS/CPT

Prior Authorization

Prior Auth Required

Conditional coverage; review criteria to confirm PA need (medium confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Claims missing required NOC narrative information or with incorrect unit reporting will be rejected as unprocessable and may show remark code M123.
All documentation must be maintained in the patient's medical record, be legible, include complete patient identification and dates of service, and be produced upon contractor request.
Medical records must include the legible signature of the physician or non-physician practitioner responsible for the care.
The submitted medical record must support the ICD-10-CM code(s), the CPT/HCPCS code(s) billed, and the medical necessity of services as stated in the applicable NCD and LCD.
Records should include relevant diagnostic laboratory studies, prior history of bleeding or infection, disease progression, prior medical/surgical therapies, vaccination response, and any other information essential to establish that the patient meets NCD/LCD coverage indications.
Accurate patient weight in kilograms must be documented prior to infusion because immune globulin dosing is mg/kg based.

Key Coverage Criteria

Billing and coding guidance in this article applies when immune globulin use meets the reasonable and necessary coverage criteria established in LCD L35093.
IVIG is covered only for indications specified as covered in the related Local Coverage Determination (LCD) and when medical necessity criteria in that LCD are met.
Coverage requires documentation that the immune globulin therapy is reasonable and necessary in accordance with LCD L34007 and applicable NCDs.
This policy addresses only the determination of medical necessity for the hospital outpatient setting for infusion and injectable therapy; the medical necessity of the pharmacologic or biologic medication itself may be reviewed separately.
Requests for select medications intended for administration in a hospital outpatient setting will be directed to a preferred alternative site of care (non-hospital affiliated outpatient facility or home).
This policy addresses only the determination of medical necessity for the hospital outpatient setting for infusion and injectable therapy; the medical necessity of the pharmacologic or biologic medication itself may be reviewed separately.

20 Active Policies

A57554, Billing and Coding: Immune Globulins

WPS-J5-L34771, Immune Globulins

WPS-J8-L34771, Immune Globulins

FIRST_COAST-L34007, Immune Globulin

A57778, Billing and Coding: Immune Globulin

NOVITAS-JH-L35093, Immune Globulin

NOVITAS-JL-L35093, Immune Globulin

A56786, Billing and Coding: Immune Globulin

BCBSNJ-DRUGS-045-EEF5008B75, Immune Globulin Subcutaneous (Hizentra, Gammagard Liquid, Gamunex-C/Gammaked, HyQvia, Cuvitru, Cutaquig, and Xembify for Subcutaneous Administration)

MODA-SCIG-IMMUNEGLOBULINSQ-361D2FC801, SCIG (immune globulin SQ): Hizentra, Gammagard Liquid, Gamunex-C, Gammaked, HyQvia, Cuvitru, Cutaquig, Xembify

BCBSMT-RX504.003, Immunoglobulin Therapy

BCBSMT-ADM1001.034, Specialty Medication Administration Site of Care

BCBSNM-RX504.003, Immunoglobulin Therapy

BCBSNM-ADM1001.034, Specialty Medication Administration Site of Care

BCBSOK-RX504.003, Immunoglobulin Therapy

BCBSOK-ADM1001.034, Specialty Medication Administration Site of Care

UMR-POL-UMR-immune-globulin-ivig-scig, Immune Globulin (IVIG and SCIG)

UMR-POL-UMR-provider-administered-drugs-soc, Provider Administered Drugs – Site of Care

SUREST-POL-SUREST-immune-globulin-ivig-scig, Immune Globulin (IVIG and SCIG)

BCBSIL-ADM1001.034, Specialty Medication Administration Site of Care

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about J1575 Sign up free

J1575, Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin

HCPCS/CPT

Prior Authorization

Prior Auth Required

Conditional coverage; review criteria to confirm PA need (medium confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Claims missing required NOC narrative information or with incorrect unit reporting will be rejected as unprocessable and may show remark code M123.
All documentation must be maintained in the patient's medical record, be legible, include complete patient identification and dates of service, and be produced upon contractor request.
Medical records must include the legible signature of the physician or non-physician practitioner responsible for the care.
The submitted medical record must support the ICD-10-CM code(s), the CPT/HCPCS code(s) billed, and the medical necessity of services as stated in the applicable NCD and LCD.
Records should include relevant diagnostic laboratory studies, prior history of bleeding or infection, disease progression, prior medical/surgical therapies, vaccination response, and any other information essential to establish that the patient meets NCD/LCD coverage indications.
Accurate patient weight in kilograms must be documented prior to infusion because immune globulin dosing is mg/kg based.

Key Coverage Criteria

Billing and coding guidance in this article applies when immune globulin use meets the reasonable and necessary coverage criteria established in LCD L35093.
IVIG is covered only for indications specified as covered in the related Local Coverage Determination (LCD) and when medical necessity criteria in that LCD are met.
Coverage requires documentation that the immune globulin therapy is reasonable and necessary in accordance with LCD L34007 and applicable NCDs.
This policy addresses only the determination of medical necessity for the hospital outpatient setting for infusion and injectable therapy; the medical necessity of the pharmacologic or biologic medication itself may be reviewed separately.
Requests for select medications intended for administration in a hospital outpatient setting will be directed to a preferred alternative site of care (non-hospital affiliated outpatient facility or home).
This policy addresses only the determination of medical necessity for the hospital outpatient setting for infusion and injectable therapy; the medical necessity of the pharmacologic or biologic medication itself may be reviewed separately.

20 Active Policies

A57554, Billing and Coding: Immune Globulins

WPS-J5-L34771, Immune Globulins

WPS-J8-L34771, Immune Globulins

FIRST_COAST-L34007, Immune Globulin

A57778, Billing and Coding: Immune Globulin

NOVITAS-JH-L35093, Immune Globulin

NOVITAS-JL-L35093, Immune Globulin

A56786, Billing and Coding: Immune Globulin

BCBSNJ-DRUGS-045-EEF5008B75, Immune Globulin Subcutaneous (Hizentra, Gammagard Liquid, Gamunex-C/Gammaked, HyQvia, Cuvitru, Cutaquig, and Xembify for Subcutaneous Administration)

MODA-SCIG-IMMUNEGLOBULINSQ-361D2FC801, SCIG (immune globulin SQ): Hizentra, Gammagard Liquid, Gamunex-C, Gammaked, HyQvia, Cuvitru, Cutaquig, Xembify

BCBSMT-RX504.003, Immunoglobulin Therapy

BCBSMT-ADM1001.034, Specialty Medication Administration Site of Care

BCBSNM-RX504.003, Immunoglobulin Therapy

BCBSNM-ADM1001.034, Specialty Medication Administration Site of Care

BCBSOK-RX504.003, Immunoglobulin Therapy

BCBSOK-ADM1001.034, Specialty Medication Administration Site of Care

UMR-POL-UMR-immune-globulin-ivig-scig, Immune Globulin (IVIG and SCIG)

UMR-POL-UMR-provider-administered-drugs-soc, Provider Administered Drugs – Site of Care

SUREST-POL-SUREST-immune-globulin-ivig-scig, Immune Globulin (IVIG and SCIG)

BCBSIL-ADM1001.034, Specialty Medication Administration Site of Care

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about J1575 Sign up free

`J1575`, Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`J1575`, Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

J1575, Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

J1575, Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`J1575`, Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin

`J1575`, Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin